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Abstract This study examined the efficacy and safety of
nifedipine sustained release (nifedipine SR) compared with
Ginkgo biloba extract as treatment for primary Raynaud’s
phenomenon (RP) in Korea. Primary RP were screened and
assigned to either the nifedipine SR group (Group N) or the
Ginkgo biloba extract group (Group G) in the ratio of 2:1.
After a run-in period of 2 weeks, patients received
treatment for 8 weeks. We observed the percent improve-
ment of the RP attack rate between before and after the 8-
week treatment. Ninety-three subjects were randomly
assigned. The percent improvement in Group N was
50.1% at 8 weeks after treatment, while it was 31.0% in
Group G (p=0.03). No serious adverse events occurred, and
almost adverse events were mild and improved without
specific treatment. nifedipine SR was more effective than
Ginkgo biloba extract for treatment of primary RP in
Korean patients. Both drugs were tolerable with primary RP
patients.
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Raynaud’s phenomenon
Introduction
Raynaud’s phenomenon (RP) was named after Dr.
Maurice Raynaud, who found a condition in which
people exposed to cold or emotional stress experienced
clearly distinguished skin-color changes in their hands
in 1862 [1]. This phenomenon, in its early stage, involves
a condition that makes hands become white or blue due to
excessive vasoconstriction when people are exposed to
cold or emotional stress. Subsequently, their finger color
changes to red by vasodilation, which is accompanied
with itching or pain. RP occurs in two forms: secondary
Raynaud’s phenomenon where there is an associated
disorder like a connective tissue disease and primary RP
where there is not [2].
The prevalence of RP varies by gender, country and
exposure to workplace vibration. One large US cohort
study found symptoms in 9.6% of women and 8.1% of
men, of whom 81% had primary RP [3]. According to
population based surveys of various ethnic groups, the
prevalence of unusual sensitive to cold on fingers is 12%,
RP in the healthy population is 3% to 5% [3]. Also, the
prevalence of RP is reported 9.5% in labor group [4], in
women 15.6–30% [5, 6], and 11–21% in general practice
setting [7]; 70–89% of RP is Primary Raynaud’s phenom-
enon of unknown origin [2, 8]. Thus, the exact prevalence
of primary RP is unknown, but primary RP is a common
clinical disorder, especially in general practice setting.
In South Korea, we demonstrated 43% patients with
abnormal cold sensation on hands or feet had RP, and
primary RP was 73% out of RP in our previous study
[9].
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Calcium channel blockers (CCBs) are the most widely
used agents for pharmacological treatment of RP [2, 10].
Among CCBs, only use of nifedipine was approved for
treatment of the disease in South Korea. There have been
many randomized controlled trials of treatment of primary
and secondary RP. However, there has been no clinical
study for primary RP in South Korean patients. Also, 83%
of primary RP patients in South Korea usually have taken
Ginkgo biloba for treatment RP; otherwise, only 5%
patients have taken CCBs for RP [9]. Furthermore, many
general practitioners in South Korea also have prescribed
Ginkgo biloba for RP (52%) [11].
Ginkgo biloba extract has been used in oriental medicine
at least since the fourteenth century. It is reputed anecdot-
ally to be potent in circulatory disorder such as intermittent
claudication [12].
We examined the efficacy and safety of nifedipine
sustained release (nifedipine SR) compared with Ginkgo
biloba extract to treat patients with primary RP.
Materials and methods
This study was a multicenter, open randomized, flexible
dose clinical trial. The subjects in this study were selected
from the Catholic University affiliated to St. Mary’s
Hospitals in South Korea. This study was conducted from
December to next March when was winter season in Korea.
The average atmospheric temperatures were −1.3°C in
December, −6.0°C in January, −5.1°C in February, and
−0.2°C in March. Primary RP patients were given a
screening number at Visit 1 (2 weeks), and they were
randomly assigned to either nifedipine SR group (Group N)
or ginkgo biloba extract group (Group G) in the ratio of 2:1
at Visit 2 (0 week).
To determine whether subjects had RP, they were asked
the following questions: (1) Are your fingers unusually
sensitive to cold? (2) Do your fingers change color when
exposed to cold? (3) Do they turn white, blue, or both?
Subjects who answered ‘Yes’ to all three questions were
diagnosed as having RP [2, 3] if a subject had normal
antinuclear antibody and normal erythrocyte sedimentation
rate, then the subject was diagnosed and enrolled with
primary RP [3].
Patients participated in this clinical trial for a total period
of 10 weeks. The patients submitted a written informed
consent during the first screening period. Also, they were
checked for vital signs, received a physical examination,
hematological tests, 12-lead ECG, and a urine test. Those
patients who were checked for the Color Chart [13] during
a Run-in Period of 2 weeks and also filled in 75% or more
of a patient diary were randomly assigned to either Group
N or Group G in the ratio of 2:1 (at visit 2, week 0), and
went on to receive treatment for 8 weeks. The color charts
were consisted of 12-point color scale and a series of
photographs illustrating blanching and cyanosis, has been
developed to assist in the diagnosis of RP in 1988. The
color charts showed a sensitivity of 90% and a specificity
of 100% [13].
Also, patient diaries were distributed to obtain accurate
and objective information related RP. Patients checked the
frequency of cold exposures, the frequency of RP attacks,
and the severity of RP attacks at the diary. The severity of
RP ranged across a continuum of value but cannot easily be
directly measured. So, we used 0–10 Visual Analog Scale
(VAS) as a measurement instrument to determine the
severity of RP attacks.
The patients had first taken for 1 week initial usual
doses, nifedipine SR 30 mg once daily or one tablet of
Ginkgo biloba extract 40 mg three times daily. The
dose of both medicines was increased; to take two
tablets each time of nifedipine SR 30 mg once daily, or
two tablets each time of Ginkgo biloba extract 40 mg
three times daily at visit three (1 week). However, if
patient had experiences an adverse event for the past
week, those patients were directed to take nifedipine
SR 20 mg once daily or to continue taking Ginkgo
biloba extract 40 mg three times daily. After one more
week (visit 4, 2 weeks), their compliance with the drug
was evaluated. If an adverse event was found, the dose
was adjusted in order to enable the subjects to continue
to take the medication for the remaining treatment
period. When the whole therapeutic process was
finished after 8 weeks of treatment, the efficacy and
safety of each treatment were evaluated at visit 5
(8 weeks). Patients were telephoned three times during
study to evaluate the safety and to improve patients’
compliance with the study. Patients also submitted a
patient diary at Visits 2, 3, 4, 5, and a premature
discontinuation visit. The World Health Organization
Quality of Life (WHO-QOL) questionnaire was evalu-
ated at Visits 2 and 5 [14, 15]. Measurement of vital
signs and a physical examination were conducted at every
visit, and an Overall Assessment Question was evaluated.
If a patient’s compliance was under 70% throughout the
whole treatment process of 8 weeks, the patient was
dropped out of this study. The flow and procedure of this
study are as shown in Fig. 1.
The primary end point in this study was the percent
improvement (Rtreat) of rate of the attack frequency after
cold exposures using color chart and patient diary.
Rtreat ¼ Rbaseline  Rweek8ð Þ=Rweek8  100 %ð Þ
Rbaseline and Rweek8 meant the real RP attack rate to the
frequency of exposure that could be caused RP attack at
baseline and week 8 visits. We also evaluated WHO-QOL,
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improvement rate of attack frequency compared to baseline
by time, and safety profiles as secondary end points.
To calculate sample size for this study, we assumed
that difference of the percent change of the attack
between two groups was 20% and considered standard
deviation of the percent change of the attack in each
group was 52. Based on these estimates, the required
sample size was 60:30 in each group with a power of
80% and an α of 0.05.
To compare general characteristics and baseline homo-
geneity of disease status between two groups, chi-squared
test and Fisher’s exact test were used for discrete variables,
and Wilcoxon’s rank sum test and two-sample t test were
performed for continuous variables. Efficacy variables were
compared with two-sample t test and performed chi squared
test to compare overall satisfaction between two groups.
Repeated ANOVA was performed to evaluate blood
pressure changes over three visits between groups. SAS
8.2 program was used for statistical analysis.
Research process, execution, evaluation, and record of
this clinical study were designed so that the we could
execute this clinical trial under the terms of Good Clinical
Practice and the principles of the Declaration of Helsinki,
and we were approved by the Independent Ethics Commit-
tee and the Investigational Review Board for the written
informed consent and other written information as provided
to patients.
In this study, the intention-to-treat (ITT) group is defined
as subjects who met all the qualifications and were
administered the test drug at least one time. If missing data
occurred due to dropout, it was corrected by Last
Observation Carried Forward. Results are basically reported
for the ITT group. Additionally, we intended to conduct a
clinical trial for a Per-Protocol (PP) group and provide the
results, and if there was a difference in analysis result
between ITT group and PP group, a cause would be




Out of the 132 patients screened, 39 subjects were dropped
out during the screening period. Finally, 93 subjects were
randomized. All randomized patients received study drugs:
61 patients received nifedipine SR (Group N) and 32
patients received ginkgo biloba extract (Group G). Sixty-
four subjects were completed (Group N: 42, Group G: 22)
this clinical trial during the 8 weeks (Fig. 2).
The randomized subjects were 26% male and 74%
female and had a mean age 39.2 years. Almost all patients
were nonsmoker (84%). At baseline, mean blood pressure
for each Group N and Group G was 118.2/73.4 and 118.4/
73.8 mmHg. Pulse per minute and body mass index were
also similar in both groups (Table 1).
The mean age of the first time when patients experiences
primary RP was before 16.5 years for Group N and before
13.9 years for Group G. 33% of Group N subjects had the
experience of primary RP treatment, 28% for Group G.
42% of Group N subjects had the 1st degree family history
of primary RP, while 10% subjects had the family history
for Group G. All subjects of both groups answered that the
hands color changed mostly when they went into the cold
outside. The answers were followed in order; when they
soaked their hands in cold water (83%), touched cold
materials (69%), and were exposed to cold wind (27%) for
example, air-conditioning room.
The mean number of exposures for a week was 18.9
times in Group N and 18.4 times in Group G during the
2-week screening period. During this time, the number of
color changes (RP attacks) within each group was 14.3
and 13.9, so the mean attack rate during the run-in
period was 73.7% in group N and 73.4% group G. The
mean intensity at exposure in each group was 5.07 and
5.05 using a VAS to measure the intensity on scale of
10. No statistical significant differences in the number of
exposures, the number of color changes, the attack rate,
or pain intensity was found between the two groups.
Primary end point efficacy
As a result of comparing the attack rate at the baseline
compared to 8 weeks after treatment in the ITT group,
the percent change was 50.1% in Group N, while it was
31.0% in Group G. That is, about 50% decrease was
found in the attack rate at the screening period
compared to the attack rate after treatment in the Group
N, which implies there is a statistically significant
difference between the two groups (Table 2). No
difference in average attack severity was found between
the two groups. A similar analysis result was shown
Fig. 1 Study flow of KOARA Study (after 2 weeks run-in period,
patients randomly assigned and received the study medications.
Patients were followed up for dose adjustment two times with 1-week
interval. Patients had taken the medication for 8 weeks in total. During
whole trial period, patients were called four times to evaluate the
safety and to improve their compliance with study (telephone symbol),
KOARA study; Korean Raynaud study)
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between PP group and ITT group (Group N; 61.3%,
Group G; 38.4% improved, p=0.037).
Secondary end points
The percent change of the attack rate at 8 weeks after
treatment compared to the baseline shows an increase
from 11.5% when the treatment was started in Group N
to 50.1% at the period of treatment was finished, and
the most significant change was shown at 2 weeks after
treatment was finished. In Group G, the attack rate was
increased from 11.4% at 1 week after treatment was
started, stayed at about 20% until 3 week after
treatment, and then increased by 31.0% at 2 weeks
after treatment was finished. However, no statistical
significance in percent change of the attack rate by
point of time was shown between the two groups (p=
0.0920; Fig. 3).
There were significant differences in overall satisfaction
for treatment from baseline for both drugs. However, Group
N produced significantly greater satisfactions at visit 4 (p=
0.04) and visit 5 (p=0.001).There was no significant
difference or change in WHO-QOL [14, 15] for both
medications.
Safety profiles
No serious adverse events or abnormal drug reactions
occurred in this study. Total subjects of experiencing drug-
related adverse events was 16 (26.2%) for Group N and
seven (21.9%) for Group G, and the total number of drug
relevant adverse events was 28 in Group N and ten in
Table 1 General characteristics of subjects
Group N (n=61) Group G (n=32) Total (n=93) p Valuea
Sex Male 12 (19.7%) 12 (37.5%) 24 (25.8%) 0.0620b
Female 49 (80.3%) 20 (62.5%) 69 (74.2%)
Age (years) 37.67±12.27 42.13±14.41 39.20±13.14 0.1528c
Smoking (N=92) Non-smoker 52 (86.7%) 25 (78.1%) 77 (83.7%) 0.0992d
Ex-smoler 1 (1.7%) 4 (12.5%) 5 (5.4%)
Current smoker 7 (11.7%) 3 (9.4%) 10 (10.9%)
Occupation Blue colar 14 (23.0%) 8 (25.0%) 22 (23.7%) 0.8252
White colar 47 (77.1%) 24 (75.0%) 71 (76.3%)
Systolic BP (mmHg) Visit 1 118.20±19.47 118.41±16.85 0.9573
Visit 2 115.15±16.19 116.91±13.84 0.6028
Diastolic BP (mmHg) Visit 1 73.82±11.77 75.31±8.48 0.7667
Visit 2 72.93±10.42 72.28±9.32 0.2451
Pulse (times/min) Visit 1 68.00±7.61 67.22±10.94 0.6880
Visit 2 66.13±6.49 67.28±8.89 0.5209
BMI (kg/m2) 22.35±6.58 21.79±2.73 0.5675
BP blood pressure, BMI body mass index
a Chi-square test
bWilcoxon’s rank sum test
c p Value of sex corresponded to testing significant difference of gender distribution (male or female) between two groups
d Fisher’s Exact Test
Screening: 132pts 
Randomization:  93pts 
Withdraw Consent: 1  
Lost to F/U: 3  
Screening Failure: 35 
Noncompliance: 3 
Insufficient effect: 1 
Lost to F/U: 2 
Protocol violation: 22 
Group N : 42 Group G : 22 
Nifedipine SR:  61pts Ginkgo:  32pts 
Fig. 2 Classification
of KOARA Study participants
(F/U follow up)
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Group G. The severity of adverse events was mostly mild
(Group N=92.9%, Group G=80.0%). Those adverse events
were improved without specific treatment. The most
commonly reported adverse event was headache from both
groups, and followed facial flushing, gastrointestinal trou-
bles, edema, and dizziness from total ITT groups (Table 3).
There was no significant difference between the two
groups in systolic or diastolic blood pressures before and
after treatment. Both blood pressure and pulse rate were
remained steady in both groups compared to the levels
recorded during the screening period.
Discussion
Although some clinical trials on patients with primary or
secondary RP using nifedipine have been performed
intermittently [16–19], this study was the first clinical trial
using South Korean patients with primary RP as its
subjects.
Previous studies have evaluated the efficacy of medi-
cines for primary RP simply on the basis of the frequency
of attacks without taking into account the diverse changes
in season or lifestyles. While in our study, the primary end
point was set to the level of improvement in attack rate,
because the frequency of exposure that the RP attack can
develop may be affected by a variety of factors including
seasonal variations and personal lifestyles [20]. In addition,
we used color chart for the purpose of more accurately
patients’ RP attack assessment [13].
The average age was 39 years and the percent of female
patients was 74% and that of male patients was 26%. This
subject pool is consistent with the report that the relevant
symptoms of primary RP develop primarily at the age range
of 20 to 40 years, and the disease is prevalent in the female
population rather than male [21]. The average age of early
onset, which in this study was found to be 15.5, is also
consistent with reported findings in other studies [22].
Cases with family history accounted for 30% on average,
which is also consistent with findings in other studies [23].
While other studies considered exposure to coldness or
stress as attack conditions or factors [3], this study
considered more concrete conditions or factors such as
when patients went out into the cold air, handled a cold
object, were exposed to operating an air conditioner,
entered a cold room, or were exposed to excessive stress,
on the basis of the data obtained from the preliminary
investigation.
In evidence-based medicine, the therapeutic principles
for primary RP should involve lifestyle modification and
medication with nifedipine [2, 3, 24]. Nevertheless, in
South Korea, herb medicines, synthetic nutrients, or blood-
circulation-improving agents have been often administered
to patients with primary RP without proven evidence [9].
Also, we previously demonstrated that many Korean
primary practitioners prescribe blood-circulation-improving
agents like Ginkgo biloba extract rather than other drugs to
patients with primary RP [11].
As a result of this study that treated Korean patients with
primary RP, nifedipine SR showed a 50% improvement in
attack rate, and a Ginkgo biloba extract preparation showed
a 30% improvement. The difference between the two
groups was statistically significant, suggesting that the
nifedipine SR has relatively dominant efficacy. Prescribed
by most physicians, Ginkgo biloba extract is less effective
than nifedipine SR. Though, because our study was absent
Table 2 Primary endpoint in intention-to-treat (ITT) group
Treatment
Group N (n=61) Group G (n=32)
Frequency of attack (%) Rbaseline 73.7±24.2 73.9±27.0
Rweek8 (after treatment) 40.7±42.4 54.5±45.9
Percent improvement of primary RP attack rate (%) 50.1±51.7 31.0±45.9*
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   * (P=0.038)
Fig. 3 Percent improvement of primary RP attack rate by time
(weeks) in KOARA ITT subjects
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a placebo arm, we could not compare the efficacy between
Ginkgo and placebo effect directly. However, considering
the efficacies of placebo in some previous studies were
similar the improvement rate of Ginkgo in our study, the
efficacy of Ginkgo was not seemed high [25, 26].
Regarding the secondary end points, as a result of
evaluating the level of improvement in attack rates over
time, Group N began with 11.5% at the baseline and
showed a 50.1% improvement during 2 weeks before
completion. Group G began with 11.4% at the first
treatment week and showed a 31.0% improvement
during 2 weeks before completion. However, the
difference between the two groups was not statistically
significant (p=0.0920). This lack of statistical signifi-
cance may be attributed to the relative short period of
treatment and small number of study populations so that if
the treatment lasted for a longer time and had more study
subjects, different outcomes from those mentioned above
are expected.
With regard to the overall satisfaction with the outcomes
after treatment, Groups N and G showed 89% and 59%,
respectively. The remarkable difference between them was
identified.
However, WHO-QOL showed no difference between the
two groups [14, 15]. The reason why there was no
significant difference in the variable, even though primary
RP has significant influence upon daily livings or activities,
may be either the relatively short period of study or that
WHO-QOL-Kor. is an inappropriate scale to evaluate the
QOL among the Korean patients with RD [11, 15].
Therefore, it is considered that new tools to evaluate the
QOL among the patients with primary RP should be
researched and developed over time.
There was no problem concerning safety in both Groups
N and G. There was no case reported in relation to
abnormal blood pressure in Group N including the patients
with primary RP who had normal blood pressure and took
30–60 mg of nifedipine SR.
Our study had several limitations. First, this study had
the relative short period of treatment. So, we could not
determine the long-term treatment effect in both groups.
Second, some of our patients were dropped out of the study
due to protocol violation. Third, because this study was the
open trial, so the investigators could recognize at which
group the patient was assigned from visit 3. This non-
blinding method would influence the evaluation of the
outcome. But, we tried to reduce this bias by using color
chart for more accurate and objective measurement of RP
attacks and the percent change improvement of attack rate
as primary end point. Forth, although capillaroscopy is a
nice additional criterion to define the presence of primary
RP, we could not use it in this study. Despite these
limitations, the result of this study provided useful
information on the efficacy, safety, and patient satisfaction
of both drugs in Korean primary RP patients.
In conclusion, as a result of comparing nifedipine SR to
Ginkgo biloba extract as treatment for Korean patients with
primary RP, nifedipine SR was more effective than Ginkgo
biloba extract and both of the drugs were safe. Prescribed
by most physicians, Ginkgo biloba extract is less effective
than nifedipine SR.
Acknowledgments This study was supported by Bayer HealthCare
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Table 3 Summary of safety profiles in ITT Group
Group N (n=61) Group G (n=32) p Valuea
Subjects who experienced drug-relevant adverse events 16 (26.2%) 7 (21.9%) 0.6438b
Serious abnormal reaction 0 0
Drug-relevant adverse events 28 10
Type of adverse events
Headache 11 (18.0%) 3 (9.4%) 0.3860
Facial flushing 6 (9.8%) 0 (0%) 0.0901
GI troubles 3 (4.9%) 3 (9.4%) 0.4107
Edema 3 (4.9%) 3 (9.4%) 0.4107
Dizziness 1 (1.6%) 1 (3.1%) 1.0000
Palpitation 1 (1.6%) 0 (0%) 1.0000
Others minor events 3 (4.9%) 0 (0%) 1.0000
Severity 0.2788
Mild 26 (92.9%) 8 (80.0%)
Moderate 2 (3.1%) 2 (20.0%)
Severe 0 (0%) 0 (0%)
a Fisher’s Exact Test
b Chi-square test
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